<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991081</url>
  </required_header>
  <id_info>
    <org_study_id>SU-09152009-3940</org_study_id>
    <secondary_id>5R21DA027331-03</secondary_id>
    <secondary_id>Protocol # 16513</secondary_id>
    <nct_id>NCT00991081</nct_id>
  </id_info>
  <brief_title>Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.</brief_title>
  <official_title>Exploratory/Developmental Study of Pharmacogenetic Smoking Cessation Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SRI International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major purpose of this exploratory developmental study will be to develop a
      patient-centered and feasible protocol for communicating genetic data as it relates to drug
      efficacy for smoking cessation inpatients receiving medication that is matched to individual
      genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therefore, our specific aims are to:

      Aim 1: Conduct formative research to develop and refine a clinical protocol for a
      multi-component smoking cessation intervention, grounded in the extended parallel process
      model, consisting of pharmacogenetic treatment (smoking cessation drug matched to each
      individual smoker's genotype) and genetic feedback (delivery of patient-centered,
      personalized genotype information and its predictive value for smoking cessation treatment
      efficacy): We will adapt, pilot-test, and refine a theoretically-grounded PGx smoking
      cessation intervention using formative interviews of 20 African-American and
      European-ancestry smokers.

      Aim 2: Conduct a mixed-methods feasibility trial randomizing treatment-seeking smokers to
      pharmacogenetic (PGx) treatment combined with genetic feedback (GF) vs. PGx treatment without
      GF for smoking cessation to examine the feasibility of the newly developed protocol in a
      primary care setting and characterize its psychological and behavioral impact: Smokers (N =
      100) will be randomized to GF vs. no GF and all will receive motivational interviewing
      (standard care/SC) and PGx treatment. We will assess the impact of GF on time to relapse,
      medication adherence, and a comprehensive assessment battery of process and cognitive,
      psychological, and behavioral outcomes. Finally, we will synthesize quantitative and
      qualitative data to revise protocols, generate hypothesizes, and estimate effect sizes for a
      follow-up R01 submission.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Abstinence at 12 Weeks Post Target Quit Date</measure>
    <time_frame>12 weeks after Target Quit Date</time_frame>
    <description>Participants reporting continuous tobacco-use abstinence 12 weeks after their Target Quit Date, whose salivary cotinine levels confirmed their abstinence, were counted as &quot;abstinent.&quot; All others were recorded as not abstinent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morisky Adherence Scale</measure>
    <time_frame>12 weeks after Target Quit Date</time_frame>
    <description>Category: Treatment Acceptability Measures: Treatment Compliance Range: 0-8 Direction: Higher values represent higher compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trust Scale</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Treatment Acceptability Measures: Trust in the clinician Range: 5-30 Direction: Higher values represent higher trust</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Communication Scale</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Treatment Acceptability Measures: Quality of verbal interaction and responsiveness during counseling sessions Range: 4-20 Direction: Higher values represent greater interaction and responsiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Scale</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Treatment Acceptability Measures: Overall satisfaction with the clinician Range: 4-20 Direction: Higher values represent higher satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Interest Scale</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Treatment Acceptability Measures: Interest in participating in recommended treatment plan Range: 1-10 Direction: Higher values represent higher treatment interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Psychological Outcome Instrument: Center for Epidemiologic Studies Depression Scale (CES-D) Measures: Interest in participating in recommended treatment plan Range: 0-60 Direction: Higher values represent increased symptoms of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatalism</measure>
    <time_frame>12 weeks after Target Quit Date</time_frame>
    <description>Category: Psychological Outcome Instrument: Powe Fatalism Inventory, 10-item, revised Measures: belief in inevitability of smoking status Range: 0-10 Direction: Higher values represent increased fatalism beliefs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intention to Quit</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Intention, confidence, and expectation of quitting smoking Range: 3-21 Direction: Higher values represent increased intention to quit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motivation</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Psychological Outcome Instrument: Single item, Likert scale from 1 to 7 Measures: Desire to quit smoking Range: 1-7 Direction: Higher values represent increased motivation to quit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Control</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Control over ability to quit smoking in the next month Range: 3-21 Direction: Higher values represent increased sense of control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Perception</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Psychological Outcome Instrument: 4-item inventory, Likert scale from 1 to 5 Measures: Perceived personal health risks from smoking Range: 4-20 Direction: Higher values represent increased perception of risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Efficacy</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Perceived ability to quit smoking in the next month Range: 3-21 Direction: Higher values represent increased self-efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Threat Minimization</measure>
    <time_frame>Within 1 week of first clinical call</time_frame>
    <description>Category: Psychological Outcome Instrument: 2-item inventory, Likert scale from 1 to 7 Measures: Perceived presence of factors that would reduce personal smoking risks Range: 2-14 Direction: Higher values represent increased risk minimization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling.
A self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
A standard 8-week course of genetically-tailored pharmacotherapy
Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)
Participants with the A2 allele (CC) were assigned to receive bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genetic feedback plus standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the standard treatment, participants in this arm received the following interventions:
Genetic feedback, verbal - During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
Genetic feedback, printed - After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counseling</intervention_name>
    <description>Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling
One week prior to the target quit date (TQD)
Two weeks post-TQD
Four weeks post-TQD</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_label>Genetic feedback plus standard treatment</arm_group_label>
    <other_name>Motivational interviewing</other_name>
    <other_name>Motivational enhancement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Self-help guide</intervention_name>
    <description>A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_label>Genetic feedback plus standard treatment</arm_group_label>
    <other_name>Support Materials</other_name>
    <other_name>Clearing the Air</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacotherapy</intervention_name>
    <description>8-week course of genetically-tailored pharmacotherapy
Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)
Participants with the A2 allele (CC) were assigned to receive bupropion</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_label>Genetic feedback plus standard treatment</arm_group_label>
    <other_name>NRT</other_name>
    <other_name>Nicotine Replacement Therapy</other_name>
    <other_name>The Patch</other_name>
    <other_name>Bupropion</other_name>
    <other_name>Zyban</other_name>
    <other_name>Aplenzin</other_name>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Genetic feedback, verbal</intervention_name>
    <description>During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment</description>
    <arm_group_label>Genetic feedback plus standard treatment</arm_group_label>
    <other_name>Pharmacogenetics</other_name>
    <other_name>Pharmacogenetic counseling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Genetic feedback, printed</intervention_name>
    <description>After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.</description>
    <arm_group_label>Genetic feedback plus standard treatment</arm_group_label>
    <other_name>Pharmacogenetics</other_name>
    <other_name>Pharmacogenetic Feedback</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion and exclusion criteria are the same for participants in the formative interviews
        (Study A) and the feasibility RCT (Study B) except that Study A will include African
        American and European American smokers and Study B will include European American smokers.

        Inclusion criteria:

          -  Adults (aged 18 or older)

          -  Currently smoke at least 10 cigarettes per day

          -  Motivated to quit smoking (&gt;=5 on a 10-point Likert scale)

          -  Have a telephone

          -  Read and speak English.

        Exclusion criteria:

          -  Any medical contraindications for transdermal nicotine replacement therapy (NRT) or
             sustained-release bupropion hydrochloride (bupropion) use based on the package labels
             (e.g., for bupropion, risk of seizure)

          -  DSM-IV Axis I diagnosis (other than nicotine dependence)

          -  Subjects who meet criteria for current major depression, or who demonstrate evidence
             of suicidal ideation at screening will be referred to treatment for depression and
             will be excluded from the study

          -  Must agree not to seek other treatment for smoking cessation during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean P David, MD SM DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SRI International</name>
      <address>
        <city>Menlo Park</city>
        <state>California</state>
        <zip>94025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McClure JB, Swan GE, St John J, Fauver R, Javitz HS, Bergen AW, Nishita D, Niaura R, Munaf√≤ MR, David SP. Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. Nicotine Tob Res. 2013 Feb;15(2):518-26. doi: 10.1093/ntr/nts173. Epub 2012 Sep 4.</citation>
    <PMID>22949583</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <results_first_submitted>June 25, 2012</results_first_submitted>
  <results_first_submitted_qc>August 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2012</results_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacogenetics</keyword>
  <keyword>genetic counseling</keyword>
  <keyword>genetic feedback</keyword>
  <keyword>nicotine replacement</keyword>
  <keyword>bupropion</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>primary care</keyword>
  <keyword>telehealth</keyword>
  <keyword>motivational interviewing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase I and Phase II participants were recruited from members of Group Health Cooperative in Seattle, WA. Of the 36 Phase II participants enrolled, 32 had been previously genotyped for an earlier study and 4 were genotyped for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Formative Interviews</title>
          <description>Phase 1 involved formative research to develop and refine a patient-centered, theoretically grounded behavioral intervention for delivering genetically-tailored smoking cessation treatment. We convened a panel of doctorate level experts (n = 10) in pharmacogenetics; smoking cessation treatment; ethical, legal and social implications of genetics research; genetic literacy; patient-clinician communications; and mixed-methods research to guide development of the pharmacogenetic treatment, GF and evaluation.
Next, smokers were asked about their familiarity with genetic concepts (e.g., DNA, genes), understanding of the roles genes play in smoking behavior and treatment response, reaction to the concept of genetically-tailoring pharmacotherapy, familiarity with the Genetic Information Nondiscrimination Act, concerns about privacy of genetic information, and interest in genetically-tailored treatment. Interviews were continued until response saturation was achieved (n = 10).</description>
        </group>
        <group group_id="P2">
          <title>Standard Treatment</title>
          <description>Received behavioral counseling by telephone and either bupropion or nicotine replacement patch</description>
        </group>
        <group group_id="P3">
          <title>Genetic Feedback Plus Standard Treatment</title>
          <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone and either bupropion or nicotine replacement patch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I, Formative Research</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">The 10 smokers interviewed were not enrolled in the Phase II RCT.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II, Randomized Control Trial</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17">Phase I interview participants were not enrolled in the Phase II RCT.</participants>
                <participants group_id="P3" count="19">Phase I interview participants were not enrolled in the Phase II RCT.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Clinical Call</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment</title>
          <description>Received behavioral counseling by telephone and either bupropion or nicotine replacement patch</description>
        </group>
        <group group_id="B2">
          <title>Genetic Feedback Plus Standard Treatment</title>
          <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone and either bupropion or nicotine replacement patch</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="10.6"/>
                    <measurement group_id="B2" value="52.7" spread="8.22"/>
                    <measurement group_id="B3" value="51.1" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuous Abstinence at 12 Weeks Post Target Quit Date</title>
        <description>Participants reporting continuous tobacco-use abstinence 12 weeks after their Target Quit Date, whose salivary cotinine levels confirmed their abstinence, were counted as &quot;abstinent.&quot; All others were recorded as not abstinent.</description>
        <time_frame>12 weeks after Target Quit Date</time_frame>
        <population>All randomized participants were included in the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Abstinence at 12 Weeks Post Target Quit Date</title>
          <description>Participants reporting continuous tobacco-use abstinence 12 weeks after their Target Quit Date, whose salivary cotinine levels confirmed their abstinence, were counted as &quot;abstinent.&quot; All others were recorded as not abstinent.</description>
          <population>All randomized participants were included in the data analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morisky Adherence Scale</title>
        <description>Category: Treatment Acceptability Measures: Treatment Compliance Range: 0-8 Direction: Higher values represent higher compliance</description>
        <time_frame>12 weeks after Target Quit Date</time_frame>
        <population>Follow-up treatment satisfaction analyses includes only those participants not lost to follow-up (n = 30)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Morisky Adherence Scale</title>
          <description>Category: Treatment Acceptability Measures: Treatment Compliance Range: 0-8 Direction: Higher values represent higher compliance</description>
          <population>Follow-up treatment satisfaction analyses includes only those participants not lost to follow-up (n = 30)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.9"/>
                    <measurement group_id="O2" value="1.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trust Scale</title>
        <description>Category: Treatment Acceptability Measures: Trust in the clinician Range: 5-30 Direction: Higher values represent higher trust</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Trust Scale</title>
          <description>Category: Treatment Acceptability Measures: Trust in the clinician Range: 5-30 Direction: Higher values represent higher trust</description>
          <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="2.5"/>
                    <measurement group_id="O2" value="18.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Communication Scale</title>
        <description>Category: Treatment Acceptability Measures: Quality of verbal interaction and responsiveness during counseling sessions Range: 4-20 Direction: Higher values represent greater interaction and responsiveness</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Communication Scale</title>
          <description>Category: Treatment Acceptability Measures: Quality of verbal interaction and responsiveness during counseling sessions Range: 4-20 Direction: Higher values represent greater interaction and responsiveness</description>
          <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="1.4"/>
                    <measurement group_id="O2" value="19.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction Scale</title>
        <description>Category: Treatment Acceptability Measures: Overall satisfaction with the clinician Range: 4-20 Direction: Higher values represent higher satisfaction</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction Scale</title>
          <description>Category: Treatment Acceptability Measures: Overall satisfaction with the clinician Range: 4-20 Direction: Higher values represent higher satisfaction</description>
          <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="1.8"/>
                    <measurement group_id="O2" value="19.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Interest Scale</title>
        <description>Category: Treatment Acceptability Measures: Interest in participating in recommended treatment plan Range: 1-10 Direction: Higher values represent higher treatment interest</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Interest Scale</title>
          <description>Category: Treatment Acceptability Measures: Interest in participating in recommended treatment plan Range: 1-10 Direction: Higher values represent higher treatment interest</description>
          <population>First treatment satisfaction analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="1.6"/>
                    <measurement group_id="O2" value="9.6" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <description>Category: Psychological Outcome Instrument: Center for Epidemiologic Studies Depression Scale (CES-D) Measures: Interest in participating in recommended treatment plan Range: 0-60 Direction: Higher values represent increased symptoms of depression</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First psychological outcome analyses include participants who received the first clinical call (n = 30)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Depression</title>
          <description>Category: Psychological Outcome Instrument: Center for Epidemiologic Studies Depression Scale (CES-D) Measures: Interest in participating in recommended treatment plan Range: 0-60 Direction: Higher values represent increased symptoms of depression</description>
          <population>First psychological outcome analyses include participants who received the first clinical call (n = 30)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="7.8"/>
                    <measurement group_id="O2" value="4.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatalism</title>
        <description>Category: Psychological Outcome Instrument: Powe Fatalism Inventory, 10-item, revised Measures: belief in inevitability of smoking status Range: 0-10 Direction: Higher values represent increased fatalism beliefs</description>
        <time_frame>12 weeks after Target Quit Date</time_frame>
        <population>Follow-up psychological outcome analyses include only those participants not lost to follow-up (n = 30)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Fatalism</title>
          <description>Category: Psychological Outcome Instrument: Powe Fatalism Inventory, 10-item, revised Measures: belief in inevitability of smoking status Range: 0-10 Direction: Higher values represent increased fatalism beliefs</description>
          <population>Follow-up psychological outcome analyses include only those participants not lost to follow-up (n = 30)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.8"/>
                    <measurement group_id="O2" value="0.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intention to Quit</title>
        <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Intention, confidence, and expectation of quitting smoking Range: 3-21 Direction: Higher values represent increased intention to quit</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Intention to Quit</title>
          <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Intention, confidence, and expectation of quitting smoking Range: 3-21 Direction: Higher values represent increased intention to quit</description>
          <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="2.9"/>
                    <measurement group_id="O2" value="19.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Motivation</title>
        <description>Category: Psychological Outcome Instrument: Single item, Likert scale from 1 to 7 Measures: Desire to quit smoking Range: 1-7 Direction: Higher values represent increased motivation to quit</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Motivation</title>
          <description>Category: Psychological Outcome Instrument: Single item, Likert scale from 1 to 7 Measures: Desire to quit smoking Range: 1-7 Direction: Higher values represent increased motivation to quit</description>
          <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.0"/>
                    <measurement group_id="O2" value="6.4" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceived Control</title>
        <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Control over ability to quit smoking in the next month Range: 3-21 Direction: Higher values represent increased sense of control</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Perceived Control</title>
          <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Control over ability to quit smoking in the next month Range: 3-21 Direction: Higher values represent increased sense of control</description>
          <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="2.5"/>
                    <measurement group_id="O2" value="13.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Perception</title>
        <description>Category: Psychological Outcome Instrument: 4-item inventory, Likert scale from 1 to 5 Measures: Perceived personal health risks from smoking Range: 4-20 Direction: Higher values represent increased perception of risk</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Perception</title>
          <description>Category: Psychological Outcome Instrument: 4-item inventory, Likert scale from 1 to 5 Measures: Perceived personal health risks from smoking Range: 4-20 Direction: Higher values represent increased perception of risk</description>
          <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="2.8"/>
                    <measurement group_id="O2" value="16.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-Efficacy</title>
        <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Perceived ability to quit smoking in the next month Range: 3-21 Direction: Higher values represent increased self-efficacy</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Efficacy</title>
          <description>Category: Psychological Outcome Instrument: 3-item inventory, Likert scale from 1 to 7 Measures: Perceived ability to quit smoking in the next month Range: 3-21 Direction: Higher values represent increased self-efficacy</description>
          <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="2.5"/>
                    <measurement group_id="O2" value="15.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Threat Minimization</title>
        <description>Category: Psychological Outcome Instrument: 2-item inventory, Likert scale from 1 to 7 Measures: Perceived presence of factors that would reduce personal smoking risks Range: 2-14 Direction: Higher values represent increased risk minimization</description>
        <time_frame>Within 1 week of first clinical call</time_frame>
        <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
          <group group_id="O2">
            <title>Genetic Feedback Plus Standard Treatment</title>
            <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
          </group>
        </group_list>
        <measure>
          <title>Threat Minimization</title>
          <description>Category: Psychological Outcome Instrument: 2-item inventory, Likert scale from 1 to 7 Measures: Perceived presence of factors that would reduce personal smoking risks Range: 2-14 Direction: Higher values represent increased risk minimization</description>
          <population>First psychological outcome analyses include participants who received the first clinical call (n = 33)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="2.9"/>
                    <measurement group_id="O2" value="7.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Treatment</title>
          <description>Received behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
        </group>
        <group group_id="E2">
          <title>Genetic Feedback Plus Standard Treatment</title>
          <description>Received genetic feedback regarding treatment selection in addition to behavioral counseling by telephone, combined with either bupropion or nicotine replacement patch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Possible selection bias as 32 of 36 participants had taken part in previous research</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sean P. David, MD, SM, DPhil</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-498-4687</phone>
      <email>spdavid@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

